Bradford Graves

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

Binh Vu, L. Vassilev, B. Vu, 2013, ACS medicinal chemistry letters.

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Thelma Thompson, David Fry, Kuo-Sen Huang, 2012, Proceedings of the National Academy of Sciences.

Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.

Binh Vu, David C Fry, B. Vu, 2013, ACS medicinal chemistry letters.

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Binh Vu, Frank Podlaski, Brian Higgins, 2013, Cancer research.

Carbocyclic Influenza Neuraminidase Inhibitors Possessing a C3‐Cyclic Amine Side Chain: Synthesis and Inhibitory Activity.

Bradford Graves, Willard Lew, Huiwei Wu, 2000 .

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Jean-Yves Blay, J. Blay, L. Vassilev, 2012, The Lancet. Oncology.

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.

Nader Fotouhi, Sung-Sau So, S. So, 2006, Journal of medicinal chemistry.

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

Jing Zhang, Zhuming Zhang, Frank Podlaski, 2013, Journal of medicinal chemistry.